1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type, Therapeutic Conditions, Route of Administration, and End User

Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type, Therapeutic Conditions, Route of Administration, and End User

  • July 2022
  • 226 pages
  • ID: 6316339
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The enzyme replacement therapy market is expected to grow from US$ 9,673.39 million in 2021 to US$ 15,184.70 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

The report highlights trends prevailing in the market and factors driving the market growth.The growth of the global enzyme replacement therapy market is attributed to the rising prevalence of lysosomal storage diseases (LSDs) and rapid regulatory approval with other marketing benefits for drug with orphan drug designation.

However, cutthroat competition among market players hinders the overall market growth.

Enzyme replacement therapy (ERT) is performed to treat congenital enzyme deficiencies by using enzyme or protein having enzymatic activity.Animal, human, and recombinant engineered enzymes are a few sources of enzyme required for treatment.

The therapy is generally applied in rare and lysosomal storage diseases, including Pompe’s disease, Fabry’s disease, Gaucher’s disease, Tay-Sachs disease, and Hurler syndrome. The most common ERT method is IV infusions, in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids.

European Medicines Agency (EMA) approves orphan drugs.For instance, according to EMA, if a product that has an orphan drug designation receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan market exclusivity.

It means the EMA may not approve any other application to market a similar drug for the same indication for 10 years.
Furthermore, in March 2016, the EMA launched the Priority Medicines ("PRIME") scheme to facilitate the development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme also provides several benefits to drug producers; once a candidate medicine is selected for PRIME. Below mentioned are the benefits provided by the EMA:
• Appoint a rapporteur from the Committee for Medicinal Products for Human Use (CHMP) and help to build knowledge ahead of a marketing-authorization application
• Early and proactive regulatory dialogue with the EMA to guide the overall development plan and regulatory strategy;
• Provide scientific advice at key development milestones, involving additional stakeholders such as health-technology-assessment bodies, to facilitate quicker access for patients to the new medicine;
• Confirm potential for accelerated assessment at the time of an application for marketing authorization.
Therefore, owing to the benefit and incentives associated with drugs designated as orphan drugs, key players operating in the market are putting efforts into developing drugs for orphan diseases. For instance, Amicus Therapeutics, Inc. recently obtained an orphan medicinal product designation in Europe from the EMA for Galafold to treat Fabry disease and the combination product, ATB200/AT2221, for treating Pompe disease. Additionally, in September 2020, Amicus Therapeutics, Inc. was granted PRIME designation for AT-GTX-501, therapy for CLN6 Batten disease.
Thus, the rapid regulatory approval with other marketing benefits for the drug with orphan drug designation is driving the market growth.
Based on enzyme type, the global enzyme replacement therapy market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes.In 2021, the other enzymes segment accounted for the largest market share.

The same segment is expected to register the highest CAGR in the market from 2022 to 2028.Based on therapeutic conditions, the global enzyme replacement therapy market is segmented into Gaucher’s disease, Fabry’s disease, Pompe’s disease, SCID, MPS, and other therapeutic conditions.

The Gaucher’s disease segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.Based on route of administration, the global enzyme replacement therapy market is bifurcated into parenteral and oral.

The parenteral segment held a larger market share in 2021 and is anticipated to register a higher CAGR during the forecast period. Based on end user, the global enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2021. However, the infusion centers segment is expected to register the highest CAGR during the forecast period.

Impact of COVID-19 Pandemic on Global Enzyme Replacement Therapy Market
The COVID-19 pandemic significantly affected the global healthcare system.To combat the spread of SAR-CoV-2 virus, governments imposed stringent policies to prevent and reduce the infection and mortality rates.

According to the Department of Emergency Medicine, in many cities across various countries in North America, emergency department (ED) visits decreased by ~40% in 2020. Moreover, outpatient appointments and elective treatments were postponed or replaced by telemedicine practices.
Moreover, the interruption of ERT during the COVID-19 pandemic may have significant consequences.Due to restrictions on hospital visits during the pandemic, many scheduled ERTs were disrupted, which led to severity of conditions in LSDs patients.

Also, lysosomal storage diseases are considered to be high risk because of respiratory, renal, and cardiac involvement.For instance, in 2021, a sample survey conducted by some doctors from Sir Ganga Ram Hospital, India, results of which were published in Indian Pediatrics, offered a glimpse into the crisis.

The survey revealed that of the 26 patients suffering from lysosomal storage disorders and receiving ERT at the hospital, 20 (77%) had significant interruption in their treatment, with an average eight missed doses.Of the 20 patients who missed multiple doses, 13 (65%) could not collect the medicine from the tertiary care center due to lack of transportation as lockdown was in place, while for two (10%), the medicine import was delayed.

Thus, such interruptions in ERT increased the suffering of LSDs patients and impacted the enzyme replacement therapy market negatively.
Various organic and inorganic strategies are adopted by companies operating in the global enzyme replacement therapy market.The organic strategies mainly include product launches and product approvals.

Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships.These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth.

Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the global enzyme replacement therapy market are listed below.
• In May 2022, AbbVie and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.
• In August 2021, the US Food and Drug Administration (FDA) approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients aged one year and above suffering from late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a person’s ability to move and breathe. Nexviazyme is an ERT designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of ERT in Pompe disease. Nexviazyme has been shown in clinical trials to provide patients with improvements in respiratory function and walking distance.
A few major primary and secondary sources referred to while preparing the report on the global enzyme replacement therapy market are the National Health and Medical Research Council (NHMRC), the Government of Canada, and the Bioprocessing Technology Institute (BTI).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

  • $ 3000
  • November 2022
  • 191 pages

The glycomic therapeutics market in South & Central America is expected to grow from US$ 8.65 billion in 2022 to US$ 20.68 billion by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028. Application ...

  • Central America
  • Therapy
  • Genomics
  • Industry analysis
  • Health Expenditure
  • Public Health Expenditure

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on